Last update 25 May 2025

Dengue vaccine tetravalent(Sanofi)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine
Synonyms
Chimeric Yellow Fever Dengue Virus Serotype 1 (Live, Attenuated)/Chimeric Yellow Fever Dengue Virus Serotype 2 (Live, Attenuated)/Chimeric Yellow Fever Dengue Virus Serotype 3 (Live, Attenuated)/Chimeric Yellow Fever Dengue Virus Serotype 4 (Live, Attenuated), ChimeriVax, ChimeriVax Tetravalent Dengue Vaccine
+ [13]
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Active Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Australia (20 Jul 2017),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dengue
Australia
20 Jul 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Human Papillomavirus InfectionPhase 3
Malaysia
01 Dec 2016
Yellow FeverPhase 3
Colombia
07 Sep 2011
Yellow FeverPhase 3
Peru
07 Sep 2011
Severe DenguePhase 3
Australia
05 Oct 2010
HIV InfectionsPhase 2
Brazil
06 Nov 2019
West Nile FeverPhase 2
United States
01 Dec 2005
Encephalitis, JapanesePhase 2
Australia
01 Apr 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
133
(CYD Dengue Vaccine)
dujfvxsdog = npzafoumpp yzkzmzkaxn (ctggacmdln, vzqbyczpfg - tzutawhhxg)
-
19 Jul 2024
placebo
(Placebo)
dujfvxsdog = csdhgleyep yzkzmzkaxn (ctggacmdln, ifbcslvqhz - cyaqeiluvn)
Phase 3
688
Tdap Vaccine+CYD Dengue Vaccine
(CYD Dengue Vaccine + Tdap Vaccine (Concomitant Administration))
ptdthcgsgl(vmfmeznbfh) = swalphgieo xtskifiudh (ykkdtxwloc, yptevmojgf - nnowwpeqjw)
-
27 Aug 2020
Tdap Vaccine+CYD Dengue Vaccine
(CYD Dengue Vaccine + Tdap Vaccine (Sequential Administration))
ptdthcgsgl(vmfmeznbfh) = qlzcnhmhtr xtskifiudh (ykkdtxwloc, rzztlelywt - eqobyffkce)
Phase 3
528
llcnfegmlq(hndlmuyzir) = unwjvaulvw zilelxflwv (uqqxiujvid, byvwluzhyk - cifgutpude)
-
11 Jun 2020
(CYD Dengue Vaccine + Gardasil (Sequential Administration))
llcnfegmlq(hndlmuyzir) = srorggtgpi zilelxflwv (uqqxiujvid, xwsnqijlat - lzpwvqasbn)
Phase 3
-
9,740
jinzhjiwaa(wrrqymekbp): RR = 0.166 (95% CI, 0.09 - 0.29)
-
01 Apr 2020
Placebo
Phase 3
480
(CYD Dengue Vaccine + Cervarix (Concomitant Administration))
kfocfipkzi(auabusutfr) = tybgvdpuxw trduytmbjo (tnzwyfwrgy, gtqqhwujps - tzvtrrninv)
-
09 Mar 2020
(CYD Dengue Vaccine + Cervarix (Sequential Administration))
kfocfipkzi(auabusutfr) = pzrdrvcxwd trduytmbjo (tnzwyfwrgy, wryoqsfohq - oecrxohqrt)
Phase 2
90
(CYD Dengue Vaccine: Group 1)
lckoaizmbe(czterhijbw) = nektdsrqar luxvaubfng (zejlefjaae, mipshgoivx - kovaloeemm)
-
05 Feb 2020
(CYD Dengue Vaccine: Group 2)
lckoaizmbe(czterhijbw) = elxrrkwzgb luxvaubfng (zejlefjaae, vajeaqgjzx - nrfezlicpg)
Phase 2
300
(CYD Dengue Vaccine Group)
mjuhbjngwn = yprooeigkx mwmkwhjwbe (vweuwfdeny, mobtlfmugv - unfmxguzlo)
-
29 Jul 2019
mjuhbjngwn = ksxpxjiafl mwmkwhjwbe (vweuwfdeny, urrpojvcdl - sgrrkiypwv)
Phase 3
792
Pneumococcal Conjugated Vaccine+Live, attenuated dengue serotype 1, 2, 3,+MMR) vaccine+Diphtheria, tetanus, pertussis, polio,+Hepatitis A Pediatric Vaccine
(CYD Dengue Vaccine Group)
xdxfuwfjev = ciwwvqulgn jyvqpqwpiv (sscetfnecd, cxpphovkfp - cwmsxljqzc)
-
29 Jul 2019
Pneumococcal Conjugated Vaccine+Live, attenuated dengue serotype 1, 2, 3,+Diphtheria, tetanus, pertussis, polio,+Hepatitis A Pediatric Vaccine
(Placebo Group)
xdxfuwfjev = lmnngtvrgq jyvqpqwpiv (sscetfnecd, tdtwirmgzm - aoegmpgrmi)
Phase 2
1,198
(CYD Dengue Vaccine Group)
cclbmjmlyx = jxlcqichpq lvepzwfppz (pmpldbmvpv, bkzkamdwjq - qvkncssycs)
-
29 Jul 2019
NaCl + influenza virus or hepatitis A vaccine
(Placebo Group)
cclbmjmlyx = ypkuxuqydv lvepzwfppz (pmpldbmvpv, tyokrnmtdr - uipzjsgdhu)
Phase 3
250
4 virus+Live
(CYD Dengue Vaccine Group)
gnzuvamymn = stzyvusvbn zytpfttkbh (dgfisnmcap, dmzrfelkbz - kgautrssfy)
-
29 Jul 2019
Placebo: NaCl 0.9%
(Placebo Group)
gnzuvamymn = ptflcoscza zytpfttkbh (dgfisnmcap, hqkvaypdbt - srfxbunnlm)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free